Apogee Therapeutics Shares Surge After Year-Long Data Show Durable Responses for Zumilokibart
Apogee Therapeutics stock climbed 15% after the company reported positive 52-week maintenance data from Part A of its Phase 2 APEX trial of zumilokibart (APG777) in patients with moderate-to-severe atopic dermatitis. The trial showed durable maintenance of response at one year for both every-three-month and every-six-month dosing schedules, with fa…